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A B S T R A C T
In the canonical pathway of IFN-I-mediated signaling, phosphorylation of STAT1 and STAT2 leads to
heterodimerization and interaction with IRF9. This complex, also known as IFN-stimulated gene factor 3
(ISGF3), then translocates into the nucleus and binds the IFN-I-stimulated response element (ISRE)
leading to the activation of transcription of over 300 interferon stimulated genes (ISGs). In addition,
STAT1 homodimers [known as g-activated factor (GAF)] are formed and translocate to the nucleus, where
they target genes containing the g-activated sequence (GAS).
The primary function of ISGF3 is to mediate a rapid and robust IFN-I activated response by regulating
transient transcription of antiviral ISGs. This requires the quick assembly of ISGF3 from its pre-existing
components STAT1, STAT2 and IRF9 and transport to the nucleus to bind ISRE-containing ISGs. The exact
events that take place in formation, nuclear translocation and DNA-binding of active ISGF3 are still not
clear.
Over the years many studies have provided evidence for the existence of a multitude of alternative
STAT2-containing (ISRE or GAS-binding) complexes involved in IFN-I signaling, emphasizing the
importance of STAT2 in the regulation of speciﬁc IFN-I-induced transcriptional programs, independent of
its involvement in the classical ISGF3 complex.
This review describes the unique role of STAT2 in differential complex formation of unphosphorylated
and phosphorylated ISGF3 components that direct constitutive and IFN-I-stimulated transcriptional
responses. In addition, we highlight the existence of a STAT1-independent IFN-I signaling pathway,
where STAT2/IRF9 can potentially substitute for the role of ISGF3 and offer a back-up response against
viral infection.
ã 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Interferons (IFNs) are a subset of cytokines that have profound
effects on many aspects of cell physiology. IFNs regulate cell
proliferation, apoptosis and inﬂammation but also take part in the
ﬁrst line of defense against viral infections. IFNs represent a family
of molecules which can be divided into three main subfamilies:
Type I, Type II and Type III. Type I (IFN-I) consist of IFNb, IFNk,
IFNv, IFNe and 13 subtypes of IFNa, type II (IFN-II) consists of the
single IFNg while type III (IFN-III) comprises IFNl1, IFNl2, IFNl3
[1,2] and recently discovered IFNl4 [3]. Almost all cells in the body
can produce IFN-I but the major producers are the plasmacytoid* Corresponding author.
E-mail address: h.bluyss@amu.edu.pl (H.A.R. Bluyssen).
http://dx.doi.org/10.1016/j.cytogfr.2016.02.010
1359-6101/ã 2016 The Authors. Published by Elsevier Ltd. This is an open access article undendritic cells (pDC) that are able to produce up to a hundred to a
thousand times more IFN-I than other cell types [4]. This usually
occurs in response to the stimulation of receptors known as
pattern recognition receptors (PRRs) by microbial products or
foreign nucleic acids [5]. These receptors are located on the cell
surface, in the cytosol or in endosomal compartments, and highly
associated with the induction of IFN-I [6]. Diverse pathways
downstream of PRRs transduce signals that converge on a few key
molecules, including the IFN-regulatory factor (IRF) family of
transcription factors that activate the transcription of genes
encoding IFN-I. In most cases, IRF3 and IRF7 are the fundamental
IRFs that are required, although others such as IRF1 [7], IRF5 [8]
and IRF8 [9] can also induce IFN-I gene transcription [10].
IFNb and all of the IFNa subtypes bind to a heterodimeric
transmembrane receptor composed of the subunits IFNAR1 and
IFNAR2. This initiates a signaling cascade through the Janus kinase-der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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pathway, a canonical cascade used by many cytokines and growth
factors to transduce their signals to the nucleus and activate target
genes. JAKs are a small family of non-receptor tyrosine kinases
with only four known mammalian members: JAK1, JAK2, JAK3, and
tyrosine kinase 2 (TYK2) that have been identiﬁed in the early
1990s [11]. The JAKs are relatively large proteins with an apparent
molecular weight of 120–130 kDa and seven deﬁned regions of
homology called the Janus homology domains (JH). The JH3-
JH4 domains of JAKs share homology with SH2 domains. JH1 is a
kinase domain important for JAK enzymatic activity and phos-
phorylation of STATs. STATs belong to the family of 7 transcription
factors, build of seven structurally and functionally conserved
regions: the N-terminal domain (ND), coiled-coil domain (CCD),
DNA-binding domain (DBD), linker domain (LD), Src-homology
2 domain (SH2), tyrosine-phosphorylation site (pY) and transcrip-
tional activation domain (TAD) [12].
As illustrated in Fig. 1, after IFN-I binding and receptor
dimerization juxtapositioning of JAK1 bound to IFNAR2 and
TYK2 bound to IFNAR1 results in increased kinase activity via
transphosphorylation [13]. Thus, JAK1 and TYK2 phosphorylate
both receptor subunits on target tyrosine residues that serve as
docking sites for the SH2 domain of a selection of STAT proteins
[14]. Receptor-bound STATs are successively phosphorylated by
JAK1 or TYK2 on a critical tyrosine residue (pTyr) stimulating theFig. 1. STAT and IRF-containing complexes in Canonical and alterative IFN-I
signaling.
After IFN-I binding and receptor dimerization juxtapositioning of JAK1 bound to
IFNAR2 and TYK2 bound to IFNAR1 results in increased kinase activity via
transphosphorylation. Thus, JAK1 and TYK2 phosphorylate both receptor subunits
on target tyrosine residues that serve as docking sites for the SH2 domain of a
selection of STAT proteins. Receptor-bound STATs are successively phosphorylated
by JAK1 or TYK2 on a critical tyrosine residue (pTyr) stimulating the formation of
SH2-pTyr mediated STAT homodimers or heterodimers that move into the nucleus
and activate transcription. In the canonical pathway phosphorylation of STAT1 and
STAT2 leads to heterodimerization and interaction with IRF9. This complex, also
known as IFN-stimulated gene factor 3 (ISGF3), then translocates into the nucleus
and binds the IFNa/b stimulated response element (ISRE) to regulate transcrip-
tion of over 300 interferon stimulated genes. In addition, STAT1 homodimers
[known as g-activated factor (GAF)] are formed and translocate to the nucleus,
where they target genes containing the g-activated sequence (GAS). Alternative
STAT2-containing ISRE- or GAS-binding complexes involved in IFN-I signaling have
been described, including STAT2-containing heterodimers of STAT1/STAT2, STAT2/
STAT3 and STAT2/STAT6. With respect to ISRE binding, the presence of “ISGF3-like”
complexes has been reported with STAT2/IRF9 and STAT2/STAT6/IRF9 as important
examples. References in brackets indicate the original publication to ﬁrst describe
the complex.formation of SH2-pTyr mediated STAT homodimers or hetero-
dimers that move into the nucleus and activate transcription.
Initially, it was believed that STATs are monomers prior to their
activation by tyrosine phosphorylation. However, accumulating
structural and functional evidence indicates that multiple
unphosphorylated STATs (U-STATs) can already exist as dimers
in living cells. The SH2 domains do not participate in this type of
dimerization and are set apart at both ends of the dimer structure;
using the N-domains STAT dimers adopt the antiparallel confor-
mation. [15,16]. Upon IFN-I induction dimerization of phosphory-
lated STATs (P-STATs) entails mutual SH2-pTyr interactions [11,17].
This parallel dimer conformation has been conﬁrmed for all STAT
proteins [18] and depends on SH2 domain interactions, whereas
the N-domains are dispensable. The details of the transition
between monomer and parallel and antiparallel dimer conforma-
tions are still under discussion. In the canonical pathway of IFN-I-
mediated signaling, phosphorylation of STAT1 on Tyr701 and
STAT2 on Tyr690 leads to heterodimerization in the parallel
conformation and interaction with IRF9 (Fig. 1: Left side). This
complex, also known as IFN-I-stimulated gene factor 3 (ISGF3)
[19], then translocates into the nucleus and binds the IFN-I-
stimulated response element (ISRE; consensus sequence
AGTTTCN2TTTCN) leading to the activation of transcription of
over 300 interferon stimulated genes (ISGs). In addition,
STAT1 homodimers [19] [known as g-activated factor (GAF)] are
formed and translocate to the nucleus, where they target genes
containing the g-activated sequence (GAS; consensus sequence
TTNCNNNAA) [20,21] (Fig. 1; Right side).
Over the years many studies have provided evidence for the
existence of a multitude of alternative ISRE or GAS-binding
complexes involved in IFN-I signaling, with a pre-dominant role of
STAT2 (Fig. 1). For example, apart from the canonical GAF complex,
STAT2-containing heterodimers of STAT1/STAT2 [22], STAT2/STAT3
[23] and STAT2/STAT6 [24] have been detected upon IFN-I
induction in different cell types with the ability to bind the GAS
sites. However, only few GAS-containing ISGs have been identiﬁed
[25] as direct targets of these alternative heterodimers. With
respect to ISRE binding, the presence of “ISGF3-like” complexes has
been reported with STAT2/IRF9 being formed independent of
STAT1 and activating transcription of a similar pool of genes as
ISGF3 in different cell types [26]. In contrast, speciﬁcally in B-cells,
activation of STAT6 by IFNa was accompanied by the formation of a
STAT2/STAT6/IRF9 complex, of which a role in B-cell speciﬁc IFN-I-
signaling was proposed [24].
The diversity of these complexes may in part explain the broad
effects and cell-type speciﬁcity of IFN-I-mediated signaling, as it
allows the transcription of a wide range of innate and adaptive
immunity-related genes dedicated to provide protection against
viral infection. It also emphasizes the important role of STAT2 in
the regulation of speciﬁc IFN-I-induced transcriptional programs,
independent of its involvement in the classical ISGF3 complex.
This review combines our latest ﬁndings [26] with recent
literature to describe the unique role of STAT2 in differential
complex formation of unphosphorylated and phosphorylated
ISGF3 components that direct constitutive and IFN-I-stimulated
transcriptional responses. In addition, we highlight the existence
of a STAT1-independent IFN-I signaling pathway, where STAT2/
IRF9 can potentially substitute for the role of ISGF3 and offer a
back-up response against viral infection [27].
2. STAT2 structure/function
STAT2 is the most structurally and functionally divergent
member of the STAT family, it was found to be activated only by
IFN-I and IFN-III. The human STAT2 gene contains 24 exons. The
amino acid sequence of human STAT2 protein as well as its
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STATs. The murine STAT2 gene has a similar structure to the human
STAT2 and also contains 24 exons. But in contrast to other STATs
mouse and human STAT2 proteins are quite different in their
amino acid sequences, especially in their C-terminal regions [28]
Typically mouse and human STAT proteins are 85–90% identical,
whereas in case of STAT2 the similarity reaches about 76% in the
ﬁrst 712 amino acids, and is lost completely after this point [29]. In
effect mouse STAT2 is larger than its human homolog and consists
of 923 amino acids [30] giving a protein of 130 kDa. Nevertheless, it
has been shown that mouse STAT2 can substitute for its human
homolog. Indeed, in human STAT2 KO cells (U6A) transfected with
murine STAT2, the response to IFNa is fully restored [28] and vice
versa, overexpression of human STAT2 in STAT2 KO mouse
ﬁbroblasts (MEFs) complements the defects in IFN-I signaling
[31]. This implies that human STAT2 and mouse STAT2 can restore
each other’s function. Moreover, STAT2 seems to be the only
member of the family to exist in a single protein variant.
Alternatively spliced STAT2 mRNA variants have been detected
both in humans (two alternative forms) and mice (three forms), no
STAT2 protein isoform has been found so far [32].
The structure of the STAT2 protein (Fig. 2 upper part) unravels
7 different domains, present in all STAT members. The N-terminal
domain of STATs [covering the ﬁrst 130 amino acids (aa)], formed
of eight short a-helices, is involved in the formation of U-STAT
dimers (Fig. 2 upper part). This region is followed by a coiled-coil
domain (aa 135–315), a superhelix structure consisting of four
a-helices wrapped around each other. In STAT2 it mediates
protein–protein interactions and is necessary for binding IRF9.
IRF9 is a member of the IRF family that share homology in their
N-terminal DNA-binding domain [33], characterized by a trypto-
phan repeat (Fig. 2 lower part). IRF9 contains a bipartite basic
nuclear localization signal (NLS) within its DBD that is recognized
by several members of the importin-a adapter family, importins-
a3, a5, and a7 [34]. Association with STAT2 is mediated by a
region within the carboxyl terminus of IRF9 and nuclear import of
STAT2 is dependent on its association with IRF9 that recognizes an
importin-a:importin-b1 complex; [34].The DNA-binding domainFig. 2. Structure of STAT2 and IRF9 proteins.
Similar to other STATs, STAT2 is composed of 7 domains: N-terminal domain (N), Coiled
2 domain (SH2), tyrosine phosphorylation site (Y) and the most differing transcriptional
among all STATs because of its TAD domain. STAT2 serves as a platform for transcriptiona
SH2 domain is necessary for mutual interactions with other STAT proteins in particular
located in the STAT2 TAD, whereas STAT2 DBD contains a nuclear localization signal
phosphorylated dimer formation. NES and NLS are recognized by exportins and importin
ISGF3. Independent of IFN-stimulation active NLS responsible for nuclear import of STA
tryptophan (W) repeat crucial for direct interactions with DNA. IRF9 also contains a bipart
members of the importin-a adapter family. The other domain building IRF9 is IRF-asso(aa 320–480) is a b-barrel structurally resembling an immuno-
globulin-like fold. This highly conserved structure in the STAT
family is responsible for binding the regulatory GAS element in
STAT-target genes, and is structurally similar to that of other
transcription factors, like p53 and NFkB. An intriguing aspect of
STAT2 biology is, although it contains a conserved DBD, it is the
only STAT family member which is unable to bind GAS sites as a
homodimer [35]. In STAT2, this domain harbors a combined NLS/
NES (nuclear export signal) that only becomes active upon
phosphorylated dimer formation [36,37]. Both the CCD and DBD
are also implicated in the interaction between U-STATs [38].
Amino acids 480–580 span the linker domain (mostly a-heli-
cal) which separates the DBD from the following SH2 domain. The
SH2 domain (aa 580–680), formed by a b-sheet surrounded by two
a-helices, participates in STAT dimerization and receptor-associa-
tion by binding to phosphorylated tyrosine residues through a
conserved arginine residue (Fig. 2 upper part). The tyrosine
phosphorylation site (Y690 in STAT2) is located directly adjacent to
the SH2 domain, and plays a crucial role in interaction with other
STATs, especially STAT1. The ﬁnal/most C-terminal amino acids
constitute the transcriptional activation domain (TAD)  which
accounts for the unique transcriptional activity of STAT dimers
upon binding to DNA [2,20]. STAT2 is best known to participate,
together with STAT1 and IRF9, in the formation of the
ISGF3 complex, which binds ISRE elements. In ISGF3,
STAT2 contributes a potent TAD but is unable to directly contact
DNA, whereas STAT1 stabilizes the complex by providing
additional DNA contacts [39]. STAT2 TAD, the longest among all
the STATs, is necessary for ISGF3-directed activation of transcrip-
tion [29,40,41]. Thus, STAT2-TAD has been shown to bind and
recruit important transcriptional co-activators, such as p300/CBP,
GCN5, DRIP150 and pp32 [41,42]. Finally, a dominant NES present
in the C-terminus of STAT2 returns the STAT2-IRF9 complex back to
the cytoplasm [34]. Consequently, STAT2/IRF9 continually shuttles
in and out of the nucleus, but the U-STAT2 NES leads to prominence
in the cytoplasm. The cytoplasmic localization of
STAT2 dramatically changes following IFN-I stimulation.-coil domain (CC), DNA-binding domain (DBD), linker domain (L), Src Homology
 activation domain (TAD). STAT2 is the most structurally and functionally divergent
l activators (TA). Despite possessing DBD STAT2 is not able to directly bind DNA. The
 with STAT1. CC domain is responsible for binding IRF9.Constantly active NES is
 (NLS) and a nuclear export signal (NES) that only become active upon tyrosine
s, respectively. STAT2 is primarily responsible for nuclear export of STAT2-IRF9 and
T2-IRF9 is located in the DBD of IRF9. Moreover, DBD of IRF9 contains a classical
ite basic nuclear localization signal (NLS) within its DBD that is recognized by several
ciation domain (IAD) essential for interplay with the CC domain of STAT2.
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The primary function of ISGF3 is to mediate a rapid and robust
IFN-I activated response by regulating transient transcription of
antiviral ISGs. This requires the quick assembly of ISGF3 from its
pre-existing components STAT1, STAT2 and IRF9 and transport to
the nucleus to bind ISRE-containing ISGs. Indeed, it was shown
almost 30 years ago by Levy et al., [43] that all the components of
ISGF3 are already present in a latent/unphosphorylated form in
unstimulated cells (Fig. 3, left panel). Therefore, activation of
ISGF3 as a nuclear, DNA-binding protein is an early event in IFN-I
signaling, being detectable within 2 min following exposure of
cells to IFNa [43]. More important, IFN treatment triggers the
association of STAT1 and STAT2 in an immunoprecipitable complex
with IRF9, which has a 20–30-fold higher ISRE binding afﬁnity than
IRF9 alone [43,44] (Fig. 3, right panel). The exact events that take
place in formation, nuclear translocation and DNA-binding of
active ISGF3 are still not clear, but a picture can be emerged from
available data in the literature that point to a central role of STAT2
(Fig. 3).
As implicated above, STAT2 is unique among the STAT proteins
because it is able to associate with the non-STAT protein IRF9
[39,45,46]. Martinez-Moczygemba et al. in 1997 [39] already
indicated that this interaction is constitutive and an U-STAT2/
IRF9 complex, without STAT1, exists in untreated cells independent
of protein modiﬁcation induced by IFNa (Fig. 3, left panel). ThisFig. 3. STAT2 in ISGF3 formation and regulation of constitutive and IFN-dependent ISG
In untreated cells (left panel) unphosphorylated STAT2 has shown to complex with IRF9 (U
STAT1/U-STAT2/IRF9). The U-STAT1 pool additionally could exist as monomers (U-STA
cytoplasm and the nucleus. U-STAT/IRF9 binds to ISRE-containing genes to mark the gen
level. U-ISGF3 likewise is able to shuttle between the cytoplasm and the nucleus and cont
U-STAT1 monomer are not able to translocate to the nucleus. Subsequently, in IFN-I 
envisioned. IFN-I induction stimulates the rapid formation of active ISGF3 from the sepa
independently move into the nucleus were they form ISGF3 on the DNA and regulate 
receptor enables active ISGF3 formation in the cytoplasm after U-STAT1 recruitment a
binding of U-ISGF3 to IFNAR could trigger formation of active ISGF3 in the cytoplasm and
active ISGF3 could result in U-ISGF3 formation by IFN-I-induced high levels of IRF9 and ST
of speciﬁc ISGs.phenomenon has been conﬁrmed since then, by many other
studies, including our recent ﬁndings where a U-STAT2/
IRF9 complex could be identiﬁed in STAT1 deﬁcient U3A cells
over-expressing STAT2 irrespective of IFN treatment [26]. More-
over, U-STAT2/IRF9 can be detected in the cytoplasm and the
nucleus, with the NLS of IRF9 being responsible for nuclear import
and the NES of STAT2 for export [34]. A recent study by Testoni
et al., using ChIP-chip experiments with the use of anti-STAT2 and
anti-phospho STAT2 antibodies, further suggested that U-STAT2 is
present in the nucleus and already bound to 62% of its target
promoters, including most “classical” ISGs, before IFNa treatment
[47]. This implies that under untreated conditions nuclear U-STAT/
IRF9 binds to ISG ISREs in the genome enabling regulation of
expression of a selection of ISGs, including those encoding
ISGF3 components at a low level. Similarly, U-STAT1 has been
recently found to drive the constitutive expression of some target
genes and to prolong the expression of speciﬁc ISGs without
phosphorylation [48]. Also, Lou et al. [49] have shown that STAT2/
IRF9 heterodimers can drive the activation of RIG-G, a “typical” ISG,
without requiring STAT2 phosphorylation. In untreated cells co-
precipitation experiments have moreover indicated that
STAT2 also interacts with STAT1, independent of IRF9, and exists
as a U-STAT1/U-STAT2 heterodimer in the anti-parallel orientation
[50,51] (Fig. 3 left panel). The U-STAT1 pool additionally could exist
as monomers (Fig. 3) or dimers (not indicated in Fig. 3). The U-
STAT1/U-STAT2 heterodimer and U-STAT1 monomer are not able
to translocate to the nucleus, since active NLS of both STAT1 and transcription.
-STAT2/IRF9) or U-STAT1 (U-STAT1/U-STAT2) or potentially take part in U-ISGF3 (U-
T1) or dimers (not indicated in the Figure). U-STAT2/IRF9 shuttles between the
ome for ISGF3 assembly upon IFN treatment and keep ISG expression at a low basal
rol basal ISG expression upon DNA-binding. The U-STAT1/U-STAT2 heterodimer and
treated cells (right panel) different scenarios of active ISGF3 formation could be
rate U-STAT2/IRF9 complex and the phosphorylated STAT1/STAT2 heterodimer, that
transient ISG expression. In contrast, IFN-induced binding of U-STAT2/IRF9 to the
nd phosphorylation, followed by rapid nuclear import and DNA binding. Likewise,
 DNA-binding after nuclear localization. The ﬁrst rapid response phase mediated by
AT1 and 2 without tyrosine phosphorylation, and subsequent prolonged expression
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dimer formation in the parallel orientation and recognition by
importin a5 [36,37,52]. STAT2 has also been described as part of
U-ISGF3, however so far this complex has only been detected in
long-term IFN-I-treated cells [48,53] where increased levels of
ISGF3 components are no longer phosphorylated but form
U-ISGF3 to regulate ISG expression or as part of a cell-growth
inhibitory mechanism upon increased cell density/crowdedness,
involving U-ISGF3-mediated gene expression [54]. However, it is
tempting to speculate that also in untreated cells U-ISGF3 can be
formed, depending on the basal level of ISGF3 components. Using
the NLS of IRF9 and NES of STAT2 it is possibly able to shuttle
between the cytoplasm and the nucleus and control basal ISG
expression upon DNA-binding.
Together, this suggests that U-STAT2 serves a unique role in the
preassembly of unphosphorylated ISGF3 sub-complexes in un-
treated cells allowing the rapid formation of active ISGF3 upon IFN-
I treatment, either in the cytoplasm or the nucleus, depending on
the level of the individual components (Fig. 3, right panel). A
crucial step in the formation of the active ISGF3 complex is the
phosphorylation of STAT1 and STAT2, to generate the parallel
STAT1/STAT2 heterodimer. Evidence exists to support a sequential
phosphorylation model in which upon IFN-I treatment STAT2 is
recruited to the receptor complex, and phosphorylated on tyrosine
690 [55]. The surrounding region (YLKHR) in STAT2 subsequently
serves as a docking site for the SH2-dependent recruitment of
STAT1 [41,56] enabling it to be phosphorylated on Y701. This
sequential model of IFNa-induced activation of STAT2 and
STAT1 selectively drives STAT1/STAT2 heterodimer formation in
the parallel orientation, and is supported by the observation that
all mutations blocking STAT2 phosphorylation (i.e. mutations of
Y690, SH2, and N-termius) also block STAT1 phosphorylation
[40,56]. What is more, in absence of STAT1 (e.g. in U3A cell line)
STAT2 is phosphorylated in response to IFNa, while in cells lacking
STAT2 (e.g. in U6A cell line) STAT1 phosphorylation is not detected,
but could be restored when these cells were transfected with
STAT2 [55]. Importantly, the phosphorylated STAT1/
STAT2 heterodimer in its parallel conformation acquires gain of
a functional NLS. This NLS is recognized by importin-a5, the same
adapter that is speciﬁc for the STAT1 tyrosine phosphorylated
homodimer [34,37,52]. STAT2 therefore has an intrinsic conditional
NLS that functions in the context of a tyrosine phosphorylated
heterodimer with STAT1, and this property of STAT2 allows it to
rescue a STAT1 molecule defective for nuclear import [34].
In which identity U-STAT2 is recruited to the IFNAR complex, is
presently unclear, but taking the above mentioned unphosphory-
lated ISGF3 sub-complexes into account, different scenarios of
active ISGF3 formation could be envisioned. According to
Martinez-Moczygemba et al., IFN-I induction stimulates the rapid
formation of active ISGF3 from the separate U-STAT2/IRF9 complex
and the P-STAT1/STAT2 heterodimer, that independently move
into the nucleus were they form ISGF3 on the DNA. In this scenario
the U-STAT1/STAT2 heterodimer is recruited to the receptor whileTable 1
Modulation of STAT1 activity and STAT2/IRF9- mediated responses.
Regulatory processes Mechanism 
Acetylation (HATs) Acetylotransferase CBP acetylates K410 and K413 in DBD of ST
SUMOylation
(SUMOs)
SUMO1 binding at STAT1 lysine K703 inhibits the phosphorylat
binding afﬁnity of STAT1 protein in response to IFN-I
SOCS inhibition Reduced SOCS1 expression enables STAT2/IRF9-dependent, ST
Dephosphorylation
(PTP)
TCP45 promotes STAT1-dephosphorylation-dependent deactiv
Viruse-mediated
inhibition
Ebola virus eVP24 protein, Sendai Virus C protein, Mumps Virthe U-STAT2/IRF9 complex may serve a guiding role by marking the
genome and recruiting the P-STAT1/STAT2 heterodimer in the
nucleus following IFN-I treatment. In contrast, IFN-induced
binding of U-STAT2/IRF9 to the receptor enables active
ISGF3 formation in the cytoplasm after U-STAT1 recruitment
and phosphorylation. Active NLS, provided by STAT1 and STAT2,
subsequently results in rapid nuclear import and DNA binding.
Likewise, binding of U-ISGF3 to IFNAR could trigger formation of
active ISGF3 in the cytoplasm and DNA-binding after nuclear
localization. In all scenarios, rapid formation of active ISGF3 could
take place that serves a robust and transient IFN-I response. More
important, this generates a more ﬂexible system of
ISGF3 activation that could be adapted to expression levels of
individual components and sub-complexes, and used in different
cell-types as well as during different stages of IFN-I signaling. The
exact stoichiometry of components in ISGF3 is as yet unresolved.
Therefore, alternative models cannot be excluded, but in the
absence of additional structural information the models remain to
be tested.
An alternative scenario was recently proposed by the group of
George Stark [53], providing evidence for the formation of
U-ISGF3 complexes in a IFN-I-dependent manner Fig. 3, Right
panel). While active ISGF3 (IRF9 and tyrosine-phosphorylated
STAT1 and 2) drives the ﬁrst rapid response phase, U-ISGF3 formed
by IFNb-induced high levels of IRF9 and STAT1 and 2 without
tyrosine phosphorylation, directed the second prolonged response.
Surprisingly, the prolonged expression of U-ISGF3-induced antivi-
ral genes was driven by distinct ISREs and restricted HCV chronic
replication.
4. STAT2 and IRF9 in STAT1-independent IFN signaling and
antiviral responses
Previously, we showed that STAT2 is also capable of forming
homodimers when phosphorylated in response to IFN-I [57]. These
STAT2 homodimers were shown to interact with IRF9 and form the
ISGF3-like complex STAT2/IRF9 that activates transcription of
ISRE-containing genes in response to IFNa [57]. Similarly, Kraus
et al. [58] and Poat et al. [59], observed that a hybrid of IRF9 and
STAT2 recapitulates interferon-stimulated gene expression in the
absence of STAT1. Different in vitro and in vivo studies have
subsequently pointed to the existence of a STAT1-independent
IFN-I signaling pathway, where STAT2/IRF9 can potentially
substitute for the role of ISGF3 [60–64] (Table 1).
In 2006 Sarkis and colleagues observed that the cytidine
deaminase APOBEC3 G (A3G) was induced in response to IFNa, in
the absence of STAT1 [65] in human liver cells and macrophages
but not in the human T-cell line H9. Expression of A3 G and other
ISGs (PKR, ISG15 and Mx1) in Hep3B liver cells was drastically
reduced when either STAT2 or IRF9 was knocked down but not
affected by STAT1 knockdown, indicating that STAT2 but not
STAT1 remained critical for the IFNa induction of these genes in
liver cells. Induction of A3 G by IFNg in Hep3B cells on the otherPublication
AT1 atracting PTP TCP45 [81]
ion of nearby localized Y701 unabling nuclear localization and DNA- [84]
AT1-independent action [27]
ation. [81]
us V protein, parainﬂuenza virus 5 V protein [73],[85–
87]
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both IFNa and IFNg induction of ISGs was dependent on STAT1,
suggesting cell-type speciﬁcity to the IFN transcriptional response.
Likewise, IFN-I induction of the second editing enzyme
p150 ADAR1 was shown to be up-regulated via STAT2 activation
in STAT1 KO mouse embryonic ﬁbroblasts [66]. This IFN-inducible
expression of ADAR1 protein also depended on JAK1 and IFNAR,
however the detailed mechanism underlying STAT1-independent
signaling by IFN-I to activate ADAR1 expression remains unclear.
Important proof for the biological signiﬁcance of STAT2/IRF9-
dependent, but STAT1 independent regulation of the retinoic acid–
induced gene G (RIG-G; also known as IFIT-3) expression was
provided by Lou and colleagues in 2009 [49]. They observed that
the STAT2/IRF9 complex effectively drives transcription of the RIG-
G gene in U3A cells upon IFNa treatment, in a STAT1-independent
manner. Similarly they noticed that the STAT2/IRF9 complex is
involved in RIG-G gene expression in NB4 cells upon signaling
cross-talk between retinoic acid and IFNa, in a STAT1-independ
manner. Interestingly, in NB4 cells the RIG-G protein expression
was prolonged upon IFNa treatment, which correlated with the
phosphorylation proﬁle of STAT2 and the presence of IRF9. In
addition they postulated a novel mechanism modulating the
expression of ISGs that accounts for the signal cross-talk between
IFNa and ATRA in NB4 cells. The effective IFNa secretion might be
one of the causes resulting in RIG-G induction in ATRA-treated
NB4 cells. Through a targeted strategy using siRNA, Fink et al. [67]
demonstrated that DUOX2 was induced by an autocrine/paracrine
pathway speciﬁcally triggered in airway epithelial cells by
synergistic action of IFNb and TNFa, and depending on STAT2/
IRF9 but entirely independent of STAT1. Unlike IFIT1,
DUOX2 induction started at 24 h post SeV infection thus, theFig. 4. STAT 2 and IRF9 in STAT1-independent IFN-I signaling.
In untreated STAT1-deﬁcient cells (left panel) unphosphorylated STAT2 has shown to 
IRF9 shuttles between the cytoplasm and the nucleus. U-STAT/IRF9 binds to ISRE-contai
induced binding of U-STAT2/IRF9 to the receptor triggers the phosphorylation and hom
STAT2/IRF9 formation in the cytoplasm, nuclear import and DNA binding (right panel). 
other hand, requires abundance of STAT2 and IRF9 protein and correlates with the delay
STAT2 phosphorylation, has suggested to mediate prolonged ISG transcription.study unveiled a key function of DUOX2 in the establishment of a
late antiviral state triggered by the synergistic autocrine/paracrine
action of IFNb and TNFa secreted during respiratory virus
infection.
The ﬁrst in vivo importance the existence and functional role of
a STAT2/IRF9 complex independent of ISGF3 stems from an early
report from Hahm and colleagues from 2005 [68]. It clearly
demonstrates that viruses (like measles virus and lymphocytic
choriomeningitis virus) evade the immune system through a IFN-I-
mediated STAT2-dependent, but STAT1-independent, mechanism.
In the brain, spleen, and liver or cultured glial and spleen cells, IRF-
7 but not IRF-9 gene expression increased with delayed kinetics in
the absence of STAT1 but not STAT2 following LCMV infection or
IFNa treatment, respectively [69]. STAT1-independent induction
of ISGs in mouse splenocytes has also been observed by Zimmerer
and colleagues [70] by comparing IFNA induced gene expression
proﬁles of splenocytes from wild type (WT) and STAT1/ mice.
Alternatively, experiments performed on STAT1-deﬁcient mice
showed that STAT2 supported the expression of ISGs and
conﬁrmed the association of STAT2 with the promoter of antiviral
genes induced in response to Dengue virus in STAT1-deﬁcient mice
[71]. Speciﬁcally, the antiviral effect of IFN was abolished in STAT1/
IFNAR1 double KO mice leaving STAT2 as the presumed signaling
factor involved in the antiviral response observed in STAT1 KO
mice. Moreover, the viral load data suggested that the antiviral
response in the single deﬁcient mice was delayed what was likely
due to inability to form ISGF3 complex, the primary transcription
complex associated with IFN-I signaling.
Likewise, Bowick et al. also showed a prolonged IFNa response
of STAT1 KO mice to Crimean-Congo hemorrhagic fever (CCHF)
viral infection, resulting in prolonged expression of classical ISGscomplex with IRF9 (U-STAT2/IRF9) or to exist as a monomer (U-STAT2). U-STAT2/
ning genes to mark the genome and keep ISG expression at a low basal level. IFN-I-
odimerization of STAT2 after sequential U-STAT2 recruitment, resulting in active
The lower DNA-afﬁnity of the STAT2/IRF9 complex as compared with ISGF3, on the
ed and prolonged nature of ISG expression. Likewise, U-STAT2/IRF9, independent of
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interferon-induced antiviral genes is delayed in a
STAT1 knockout mouse model of CCHF.
A parallel study performed by Abdul-Sater et al. [27]
demonstrated that, in primary Stat1 KO BMM cells, STAT2 can
associate with IRF9 to drive the delayed expression of a subset of
ISGs important in the innate response to L. pneumophila, Dengue
virus, as well as potentially other viruses. In this study, STAT2 was
identiﬁed as a key component of the STAT1-independent mecha-
nism of protection against DENV infection in mice, and demon-
strated that both STAT1 and STAT2 possess the ability to
independently limit the severity of DENV pathogenesis. For many
viruses, inhibition of STAT-mediated signaling is a major mecha-
nism to evade antiviral responses. Therefore, these data suggest
that DENV-mediated inactivation of STAT1 function alone is not
sufﬁcient to neutralize antiviral responses, and it is tempting to
speculate that the STAT2/IRF9 pathway evolved as a backup
response to defend against pathogens that impede STAT1 activity
[27] (e.g., Paramyxovirus [73,74]).
5. ISGF3 vs. STAT2/IRF9
Recently, we provided further insight into the genome-wide
transcriptional regulation and the biological implications of STAT2/
IRF9-dependent IFNa signaling as compared to ISGF3 [26]. In
STAT1-defeicient human and mouse cells stably overexpressing
STAT2 we observed that the IFNa-induced expression of typical
ISGs correlated with the kinetics of STAT2 phosphorylation, and
the presence of a STAT2/IRF9 complex. Subsequently, we identiﬁed
120 known antiviral ISRE-containing ISGs commonly up-
regulated by STAT2/IRF9 and ISGF3. The STAT2/IRF9-directed ISG
expression proﬁle was prolonged as compared with the early and
transient response mediated by ISGF3 implying that STAT2/
IRF9 and ISGF3 regulate expression of a common set of ISGs with
different kinetics. Among the commonly induced genes in both
human and mouse cell lines were many known ISGs and functional
analysis revealed their main role in the antiviral response. Within
the promoter of all of these genes, we conﬁrmed the presence of a
classical ISGF3-binding ISRE. Indeed, STAT2/IRF9 was able to
trigger an antiviral response upon encephalomyocarditis virus
(EMCV) and vesicular stomatitis Indiana virus (VSV) offering
additional proof for the functional overlap between STAT2/
IRF9 and ISGF3. Thus, STAT2/IRF9 not only activates expression
of known antiviral ISGs, but also has a biological function in the
reconstitution of the antiviral response in cells lacking STAT1. This
is in agreement with ﬁndings of Kraus et al. [58] and Poat et al. [59],
who observed that expression of the IRF9/STAT2 fusion can
recapitulate the IFN-I biological response, producing a cellular
antiviral state that protects cells from RNA and DNA virus-induced
cytopathic effects and inhibits virus replication.
The ISGF3 complex, consisting of STAT1/STAT2 heterodimers
and IRF9, binds a composite DNA sequence (AGTTTCNNTTTCN) in
which IRF9 contributes most of the DNA-binding speciﬁcity by
recognizing the core sequence of the ISRE [75]. STAT1 contributes
necessary contacts with DNA which raises the afﬁnity of ISGF3 for
DNA above a minimal threshold provided by IRF9 alone.
STAT2 contains a transactivation domain that is essential for
transcriptional activity of ISGF3 [76]. In the STAT2/IRF9 complex,
STAT2 homodimers in conjunction with IRF9 recognize only a core
ISRE sequence, resulting in a lower DNA-binding afﬁnity as
compared with ISGF3 [57]. The presence of classical ISGF3-binding
ISRE sequences, also bound by STAT2/IRF9, in the promoters of the
commonly induced ISGs in both human and mouse cell lines, thus
could explain the functional overlap of STAT2/IRF9 with ISGF3.
In the absence of STAT1 a model could therefore be proposed in
untreated cells in which U-STAT2/IRF9 shuttles between thecytoplasm and the nucleus, with the ability to bind DNA and
potentially regulate expression of a selection of ISGs (Fig. 4, left
panel). IFN-I-induced binding of U-STAT2/IRF9 to the receptor
triggers the phosphorylation and homodimerization of STAT2 after
sequential U-STAT2 recruitment, resulting in active STAT2/IRF9
formation in the cytoplasm (Fig. 4, right panel). Active NLS,
provided by STAT2 and IRF9, subsequently results in nuclear
import and DNA binding. We propose that the phosphorylated
STAT2 homodimer in active STAT2/IRF9 increases stability and
transcriptional activity as compared to U-STAT2/IRF9, although
evidence is lacking to support this. The lower DNA-afﬁnity of the
STAT2/IRF9 complex as compared with ISGF3, on the other hand,
requires abundance of STAT2 and IRF9 protein and correlates with
the delayed and prolonged nature of its IFNa-mediated activity
(Fig. 4, right panel). Therefore, in the absence of STAT1 a certain
threshold amount of STAT2 and IRF9 must be reached to allow
STAT2 phosphorylation and STAT2/IRF9-mediated transcription.
An alternative scenario was recently proposed by Lou et al. in
2009 [49], who suggested that in all-trans retinoic acid (ATRA)-
treated cells, the autocrine/paracrine action of secreted IFNa
mediates the regulation of RIG-G gene by U-STAT2/IRF9, indepen-
dent of STAT2 phosphorylation, requiring abundance of
U-STAT2 and IRF9 proteins and mediating prolonged transcription
(Fig. 4, right panel). So far it is not clear if IFN-I-dependent
expression of other ISRE-containing genes is affected by this
complex in the absence of STAT1.
6. New STAT2 functions
In addition, in the human STAT1 KO cells overexpressing
STAT2 we identiﬁed a group of ISGs, including CCL8 and CX3CL1,
whose response to IFNa was absent from wild type cells [26].
Moreover, the IFN-I-induced delayed expression of these genes
depended on both STAT2 and IRF9 and were therefore classiﬁed as
‘STAT2/IRF9-speciﬁc’. Detailed promoter analysis did not identify a
classical ISGF3-binding ISRE, predicting that a DNA sequence
distinct from the ISRE is involved in the regulation of these ‘STAT2/
IRF9-speciﬁc’ genes. Interestingly, Schmid et al. in 2010 [77]
identiﬁed a group of genes speciﬁcally regulated by IRF7. It was
shown that IRF7 can induce an ISGF3-like transcriptome in the
absence of IFN-I signaling and among the up-regulated genes were
many known antiviral ISGs, containing universal ISREs recognized
by ISGF3 as well as IRF7. Alternatively, IRF7 regulated genes
through an ‘IRF7-speciﬁc ISRE’ (TTTGNCTTT) that resembles a core
ISRE [75]. It could be that a similar core ISRE sequence is required in
the regulation of the ‘STAT2/IRF9-speciﬁc’ genes such as CCL8 and
CX3CL1, whose response to IFN-I was absent in WT 2fTGH cells. On
the other hand, it is entirely possible that STAT2/IRF9 is capable of
binding to a DNA sequence distinct from the ISRE element. Future
ChIP-seq experiments will hopefully reveal the identity of this
mechanism.
Looking closer at the function of these ‘STAT2/IRF9-speciﬁc’
genes we could predict a novel role for STAT2. Gene ontology
analysis revealed their main involvement in cell chemotaxis or
leukocyte migration (not shown), pointing to a role of STAT2 in
inﬂammation. In agreement with this are ﬁndings from the group
of Ian Campbell [78] who observed that IFN-I-driven lethal disease
in LCMV-infected STAT1 KO mice was mediated by STAT2- and
IRF9-dependent pathways. IRF7 was subsequently identiﬁed as the
key transcriptional regulator of IFN-I production during LCMV
infection that was signiﬁcantly induced in a STAT1-independent
fashion in the spleen and central nervous system during LCMV
infection [79]. Strikingly, this was accompanied by elevated
expression of various cytokine genes in tissues and in serum,
being responsible for severe multiorgan immune pathology. It
suggests that during LCMV infection, in the absence of STAT1, [79]
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likewise coincides with a broader spectrum of functions for this
alternative IFN-I induced complex.
7. Modulation of STAT1 activity and STAT2/IRF9- mediated
responses
IFN-I signaling is regulated by other post-translational modiﬁ-
cation mechanisms, including, acetylation, SUMOylation and
suppression through SOCS proteins or phosphatases. Indeed,
speciﬁc modulation of STAT1 activity has appeared as a potential
mechanism to drive STAT2/IRF9-dependent, but STAT1-indepen-
dent responses (Table 1).
For example, Abdul-Sater et al. [27] showed that the delayed
kinetics of STAT2 activation and ISG expression in DENV infected
primary Stat1KO BMM cells correlated with a shorter STAT2 t1/2. It
suggested that these cells may not express sufﬁcient levels of
STAT2 to enable a rapid and robust signaling response observed in
IFN-I treated WT cells. Second, the delayed STAT2 activation alsoFig. 5. Abundance and phosphorylation kinetics of ISGF3 components dictate the natu
After IFN-I binding and receptor dimerization juxtapositioning of JAK1 bound to
transphosphorylation. Thus, JAK1 and TYK2 phosphorylate both receptor subunits on tar
STAT proteins. Receptor-bound STATs are successively phosphorylated by JAK1 or TYK2 o
STAT homodimers or heterodimers which then form higher complexes with IRF9. Abu
formed complex(-es) and duration of IFN-I responses. Various mechanisms have show
(HATs), dephosphorylation by protein tyrosine phosphatases (PTPs), SOCS inhibition or 
types with a transient STAT1 and STAT2 phosphorylation pattern IFN-I signaling is medi
STAT2 and IRF9, prolonged STAT2 phosphorylation and transient STAT1 activity, ﬁrstly IS
robust and prolonged IFN-I response. At last in cells with increased levels of STAT2 and
activity, the STAT2/IRF9 complex alone can mediate a prolonged IFN-I response.multifaassociated with a prolonged activity of JAK1 and reduced levels of
suppressor of cytokine signaling 1 (SOCS1) [80]. SOCS1 inhibits JAK
tyrosine kinase activity directly through its kinase inhibitory
region (KIR) and consequently acts like a negative feedback loop for
IFN-I signaling. In STAT1 KO BMM cells, as well as in human and
mouse STAT1 KO cells overexpressing STAT2 cells [26] from our
recent work (data not shown), reduced SOCS1 expression enables
STAT2/IRF9-dependent, but STAT1 independent regulation and
delayed expression of a subset of ISGs important in the innate
response to viral infection.
STAT1 signaling also depends on the phospho-acetyl switch
which is driven by antagonistic activity of acetyltransferase CBP
and deacetylase HDAC3 [81]. STAT1 is acetylated within its DNA-
binding domain on the K410 and K413 lysine residues. Such
acetylated lysines attract protein tyrosine phosphatase TCP45 and
promote STAT1-speciﬁc dephosphorylation-dependent deactiva-
tion. In particular, inhibition of STAT1 (but not STAT2) by
acetylation has been observed in many systems [82] leading to
termination of IFN signaling. Therefore, the presence of acetylatedre and duration of ISGF3 and STAT2/IRF9-mediated IFN-I responses.
 IFNAR2 and TYK2 bound to IFNAR1 results in increased kinase activity via
get tyrosine residues that serve as docking sites for the SH2 domain of a selection of
n a critical tyrosine residue (pTyr) stimulating the formation of SH2-pTyr mediated
ndance and phosphorylation kinetics of STAT1, STAT2 and IRF9 dictate the type of
n to inﬂuence this such as SUMOylation, acetylation by Histone acetyltransferases
multivariate viral strategies used to manipulate the host immune response. In cell
ated pre-dominantly by ISGF3, whereas under circumstances of increased levels of
GF3 is acting and then the balance is tilting towards STAT2/IRF9 what results in the
 low basal levels of IRF9, prolonged phosphorylation of STAT2 and transient STAT1
rious
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IFN-I-dependent transcription. As STAT1 acetylation in combina-
tion with speciﬁc dephosphorylation does not affect STAT2, it could
be that under certain conditions STAT2/IRF9 may allow continua-
tion of the IFNa response and prolonged transcription.
STAT1 activity is importantly affected by SUMOylation, which is
a reversible posttranslational modiﬁcation that relies on covalent
attachment of SUMO groups [83]. STAT1 SUMOylation occurs on
lysine 703 and inhibits phosphorylation of tyrosine 701 and STAT1
dimerization [84]. Interestingly, SUMO1 and 3 paralogs were
shown to decrease phosphorylation and nuclear localization of
STAT1 protein in response to both IFNa and IFNg, whereas
STAT2 was unaffected. Moreover, in SUMO1 and 3 overexpressing
cells IFNa treatment induced the formation of an ISGF3-like
complex consisting of STAT2 but not STAT1 that could bind the ISRE
and activate transcription [83].
For many viruses, inhibition of STAT-mediated signaling is a
major mechanism to evade antiviral responses. Not only STAT
phosphorylation can be precluded, but also STAT dimerization can
be disturbed or STAT proteins can be targeted for degradation [1].
Several studies revealed that Ebola virus protein eVP24 can
efﬁciently compete with the phosphotyrosine of STAT1 for binding
with karyopherin alpha nuclear transporter family member
KPNA5, hence undermine nuclear import of activated STAT1
[85]. Similarly, the large form of the Sendai Virus C protein can
directly bind to STAT1 promoting its ubiquitination and following
degradation, and counteracting the antiviral state in infected and
neighboring cells, as well as programmed cell death [86]. Likewise,
the V protein of Mumps activates ubiquitin-dependent STAT1
degradation [87]. Therefore, it is tempting to speculate that the
STAT2/IRF9 pathway evolved as a backup response to defend
against pathogens that impede STAT1 activity.
8. Conclusions
STAT2 uniquely participates in differential complex formation
of unphosphorylated and phosphorylated ISGF3 components that,
after nuclear translocation and DNA-binding, direct constitutive
and transient IFN-I-stimulated transcriptional responses. In ISGF3,
the rapid assembly and nuclear translocation as well as the strong
DNA-binding afﬁnity and potent transcriptional activity are
incorporated in the crucial interactions of a phosphorylated
STAT1/STAT2 heterodimer with IRF9, to mediate a rapid and
transient response to IFN-I. In addition, STAT2 controls a STAT1-
independent IFNa signaling pathway, where STAT2 homodimers in
conjunction with IRF9 can potentially substitute for the role of
ISGF3 [26] and offer a back-up response against viral infection. The
lower DNA-afﬁnity of the STAT2/IRF9 complex as compared with
ISGF3, on the other hand, requires abundance of STAT2 and
IRF9 protein and correlates with the delayed and prolonged nature
of its IFN-I-mediated activity. On the other hand, a novel function
for STAT2 appears in untreated cells as an U-STAT2/IRF9 DNA-
binding complex to mark the genome for ISGF3 assembly upon
IFN-I treatment and keep ISG expression at a low basal level ready
for a rapid response against viral infection.
These different complexes coincide with the hypothesis that
abundance and phosphorylation kinetics of ISGF3 components
dictate the nature and duration of IFNa responses (Fig. 5). In cell
types with a transient STAT1 and STAT2 phosphorylation pattern
ISGF3 is the pre-dominant mediator of IFN-I signaling. In contrast,
in cells with elevated levels of STAT2 and prolonged
STAT2 phosphorylation STAT2/IRF9 can either coexist with the
classical ISGF3 complex or act solely, depending on the level of
STAT1 and IRF9 (Fig. 5). This situation is very likely to be cell-type-
speciﬁc, where both complexes may be involved in different stages
of the antiviral response; ISGF3 stimulating a rapid and transientantiviral response and STAT2/IRF9 being responsible for a
prolonged antiviral response [88]. This generates a more ﬂexible
system of ISGF3 activation that could be adapted to expression
levels of individual components and sub-complexes, and used in
different cell-types as well as during different stages of IFN-I
signaling.
More important, evidence is accumulating to suggest that the
contribution of ISGF3 and/or STAT2/IRF9 in the overall IFN-I
response depends on the modulation of STAT1 activity by other
post-translational modiﬁcation mechanisms including, acetyla-
tion, SUMOylation and suppression through SOCS proteins or
phosphatases (Fig. 5). Very often, viruses can still replicate and
cause disease in vivo, because they have the capacity to block the
activation of speciﬁc components of the IFN-I-induced signaling
cascade, including STAT1, thus providing an additional setting in
which the STAT2/IRF9 pathway could offer a backup response. This
also highlights the fact that the presence of alternative antiviral
responses could provide the host with distinct survival advantages.
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